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Pharmacologic inhibition of reactive gliosis blocks
TNF-α-mediated neuronal apoptosis
Izhar Livne-Bar1,2, Susy Lam1, Darren Chan1, Xiaoxin Guo1, Idil Askar1, Adrian Nahirnyj1, John G Flanagan2 and Jeremy M Sivak*,1,3
Reactive gliosis is an early pathological feature common to most neurodegenerative diseases, yet its regulation and impact remain
poorly understood. Normally astrocytes maintain a critical homeostatic balance. After stress or injury they undergo rapid
parainflammatory activation, characterized by hypertrophy, and increased polymerization of type III intermediate filaments (IFs),
particularly glial fibrillary acidic protein and vimentin. However, the consequences of IF dynamics in the adult CNS remains unclear,
and no pharmacologic tools have been available to target this mechanism in vivo. The mammalian retina is an accessible model to
study the regulation of astrocyte stress responses, and their influence on retinal neuronal homeostasis. In particular, our work and
others have implicated p38 mitogen-activated protein kinase (MAPK) signaling as a key regulator of glutamate recycling,
antioxidant activity and cytokine secretion by astrocytes and related Müller glia, with potent influences on neighboring neurons.
Here we report experiments with the small molecule inhibitor, withaferin A (WFA), to specifically block type III IF dynamics in vivo.
WFA was administered in a model of metabolic retinal injury induced by kainic acid, and in combination with a recent model of
debridement-induced astrocyte reactivity. We show that WFA specifically targets IFs and reduces astrocyte and Müller glial
reactivity in vivo. Inhibition of glial IF polymerization blocked p38 MAPK-dependent secretion of TNF-α, resulting in markedly
reduced neuronal apoptosis. To our knowledge this is the first study to demonstrate that pharmacologic inhibition of IF dynamics
in reactive glia protects neurons in vivo.
Cell Death and Disease (2016) 7, e2386; doi:10.1038/cddis.2016.277; published online 29 September 2016
Astrocyte reactivity (reactive gliosis) is an early pathological
feature common to most neurodegenerative diseases, yet its
regulation and impact remains poorly understood. In the
healthy central nervous system (CNS), astrocytes coordinate
homeostatic vascular perfusion, free radical detoxification
and neurotransmitter recycling.1,2 Injury or stress induces a
phenotypic switch, whose cardinal features are cellular
hypertrophy and increased expression and polymerization of
type III intermediate filaments (IFs), particularly glial fibrillary
acidic protein (GFAP).3–5 The role of intermediate filaments in
reactive gliosis remains unclear.3,6–9 Genetic deletion of IFs
GFAP and vimentin have been shown to promote axonal
outgrowth and regeneration in developing neurons and
models of CNS injury,10–12 yet result in developmental defects
to inner retinal function13 and increased damage in models of
Alzheimer’s disease.14 Genetically, GFAP gain of function
mutations associated with Alexander’s disease induce a p38
mitogen-activated protein kinase (MAPK)-dependent
pathology.15 However, no pharmacologic tools have been
available to specifically modulate and explore this reactive
switch in the context of pathological CNS injury. Consequently,
strategies to therapeutically target the reactive switch have
remain challenging to explore.
Withaferin A (WFA) is a small molecule withanolide that is a
potent and specific inhibitor of type III intermediate filament
dynamics.16–18 Its activity has been most closely studied with
respect to vimentin rearrangement and phosphorylation in
the context of angiogenesis, fibrosis and cancer, through
downstream effects on inflammatory signaling and cell
proliferation.19–24 Interestingly, WFA has been reported to
regulate vimentin-mediated activation of MAPKs in a context
dependent manner, as well as NFκB.25,26 Recently Bargagna-
Mohan et al.27 reported that, in addition to vimentin, WFA also
binds covalently to GFAP at cysteine 294. In these studies
WFA impaired GFAP filament assembly and polymerization in
cultured astrocytes, and in vivo in retinal astrocytes and
related Müller glia in a model of injury-induced gliosis.27
Therefore, WFA presents a novel tool to test the pharmaco-
logic blockade of intermediate filament remodeling during
gliosis. However, the consequences of WFA disruption of IFs
on neuronal damage has not been studied.
We have previously used the retina as a uniquely accessible
model to study the regulation of astrocyte stress responses, and
their influence on retinal neuronal survival.28–30 In the human
and rodent eye retinal ganglion cells (RGCs) and amacrine cells
of the inner retina maintain a delicate homeostatic balance and
are particularly vulnerable to excitotoxic andmetabolic damage,
mediated in part through non-cell autonomous interactions with
neighboring glia.31–34 In addition, our work and others has
implicated signaling through p38 MAPKs as key regulators of
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glutamate recycling, antioxidant activity, and cytokine secretion
in neighboring stress-activated retinal astrocytes and
Müller glia.29,35–37 Here we take advantage of a model of
induced retinal astrocyte reactivity to establish whether WFA,
and the selective p38 MAPK inhibitor SB203580 (SB), affect
neuronal apoptosis in a mouse model of excitotoxic injury.
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Results
WFA and SB treatment blocks glial reactivity and rescues
retinal neurons from apoptosis. For the present series of
experiments we utilized a well-established excitotoxic model
of inner retinal injury that is closely associated with reactivity
of resident astrocytes and Müller glia.33,38–42 Intraocular
injection of kainic acid (KA) consistently generated rapid
accumulation of GFAP in retinal astrocytes and Müller fibers
(Figure 1a and c), and apoptosis of RGCs and amacrine cells
in the ganglion cell layer (GCL) and inner nuclear layer (INL)
by 18 h (Figure 1b and d). This method facilitates rapid and
accurate quantification of markers for the resulting neuronal
apoptosis and glial reactivity.28 In order to study the influence
of IF dynamics on this model, we first tested the efficacy of
WFA and the selective p38α and β-MAPK inhibitor
SB203580 (SB).
Mice were administered either WFA (2 mg/kg), or vehicle
control. WFA strongly reduced GFAP levels in inner retinal
astrocytes and Müller fibers following KA challenge
(Figure 1e). WFA treatment also resulted in a corresponding
marked reduction in inner retinal apoptosis in the GCL and INL
compared with control mice (Figure 1f). As we have previously
determined that blocking p38 MAPK reduces activation of
retinal astrocytes in vitro,29 we also tested intravitreal
administration of SB (2 mM), which similarly strongly reduced
GFAP staining (Figure 1g), and markedly decreased neuronal
apoptosis compared with vehicle (Figure 1h).
To quantify the extent of retinal gliosis and neuronal
apoptosis in these studies, we followed established proce-
dures to count activated Müller glia and GCL death. However,
similar patterns were also observed in the INL (Figure 1a–h).
For gliosis quantification, the number of GFAP-positive
processes crossing the inner plexiform layer were counted
across the retina in multiple sections through the level of the
optic nerve head, and averaged for multiple animals.43 On
adjacent sections TUNEL-positive cells in the GCL were
similarly quantified across the retina and averaged by
established methods.28,44–46 These analyses confirmed a
highly significant 80% reduction in GFAP-positive processes
for both WFA and SB, and 60% and 80% reductions in GCL
apoptosis, respectively (Figure 1i and j). Therefore, adminis-
tration of WFA or SB effectively blocked KA-induced reactivity
and apoptosis in the retina.
WFA treatment compromises intermediate filament poly-
merization. In order to confirm the direct activity of WFA on
astrocyte IFs, we treated cultured retinal astrocytes with the
drug for subsequent analyses by fluorescent microscopy.
Highly enriched retinal astrocyte cultures were established
from adult rats according to our published methods.28–30 We
have previously shown that these cells present typical
astrocytic morphology, and a variety of specific markers,
including GFAP, vimentin, Pax-2, glutamine synthetase (GS)
and S100A.29 They also robustly respond to metabolic and
oxidative stress with p38 MAPK-dependent changes in
activation markers, secreted cytokines and antioxidants.29
In the present study, vimentin and GFAP filaments were
assessed in retinal astrocytes by fluorescent microscopy
following treatment with 2 μM WFA or vehicle. Both vimentin
and GFAP showed reduced filamentous signal and the
formation of short aggregates following WFA exposure
(Figure 2a–b and d–e). In comparison, staining for actin
showed no effect on filament assembly (Figure 2c and f).
These specific WFA effects on IF polymerization are
consistent with previous reports.16,27
To confirm these effects in vivo, retinas from control and
WFA-treated mice were also flatmounted and probed for GFAP
and vimentin, followed by imaging with confocal microscopy.
The intensity and extent of GFAP and vimentin filaments was
reduced in WFA-treated animals compared with vehicle,
consistent with our in vitro results (Figure 2g–h and j–k).
By comparison, staining for the astrocyte marker S100 was not
strongly affected and indicated similar numbers of cells in
treated and vehicle samples, but with apparent changes to
astrocyte morphology (Figure 2i and l). Likewise, there were no
WFA-induced changes in staining for GS in retinal sections
(Supplementary Figure 1). In general the treated astrocytes
appeared smaller with fewer processes (Figure 2j–l).
A non-invasive injury model of induced retinal glial
activation. Demonstrating IF-dependent effects in vivo is
challenging due to developmental and compensatory effects
of induced gene deletions, and the intimate assoc-
iations between glial reactivity and neurodegeneration. For
this purpose we took advantage of a recently described
model of induced retinal glial activation. Bargagna-Mohan
et al. reported that mechanical corneal debridement-induced
sensitive and robust retinal astrogliosis, but did not cause any
apparent changes in retinal morphology or pathology
compared with untreated eyes.27,47 This new model of
retinal astrocyte reactivity provides a unique opportunity
for investigating the influence of injury-induced glial
reactivity on neurovascular tissue. We decided to use
this assay to test the reactivity-dependent effects of WFA
and SB. In order to adapt the model for this purpose, we first
set out to reproduce and expand the previously reported
results.
According to well-established methods the corneal epithe-
lium was transiently removed by gentle mechanical debride-
ment, according to our published procedure.48 The epithelium
resurfaces within 1–2 days accompanied by transient corneal
inflammation and neovascularization. Bargagna-Mohan et al.
Figure 1 WFA and SB inhibit retinal gliosis and apoptosis. (a and b) Intraocular injection of vehicle alone leads to no increase in GFAP stained glial fibers or TUNEL stained
apoptotic cells. (c and d) Injection of KA induces increased GFAP staining of retinal astrocytes (arrowheads), and induced staining in Müller fibers (arrows) and apoptotic death of
cells in the GCL (arrows) and INL by 18 h. (e and f) Treatment with WFA blocks the increased GFAP and TUNEL staining. (g and h) Treatment with SB203580 (SB) similarly
blocks the increased GFAP and TUNEL staining. (i) Quantification of the GFAP and TUNEL results from multiple animals showing fold change compared with contralateral control
eyes (bars indicate S.E., **Po0.01, n⩾ 4). Scale bar indicates 50 μm. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. All of the following panels and
images are oriented in the same way
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reported that by 7 days post injury a robust increase in GFAP is
induced in astrocytes and Müller fibers.27,47 Following the
same procedure we also observed a strong increase in retinal
GFAP staining compared with non-debrided controls (Figure
3a and c). Also consistent with the previous reports, there was
no major change to retinal morphology or evidence of
apoptosis (Figure 3b and d). As a second confirmation of
increased gliosis, we performed western blotting for GFAP,
and also for GS; a key glutamate recycling enzyme that is
characteristically reduced in activated astrocytes.49,50 Con-
sistent with the immunofluorescence images, GFAP was
significantly increased and GS significantly decreased in
retinas isolated from debrided eyes, compared with non-
debrided controls (Figure 3e and f).
To control for possible inflammatory effects we probed
retinas from debrided eyes for CD68, GR-1 and F4/80, for
evidence of activated microglia, neutrophils and macro-
phages, respectively (Figure 3g–i). Little or no staining was
Figure 2 WFA treatment inhibits IF dynamics. (a–f) Treatment of cultured retinal astrocytes with 2.0 μm WFA resulted in reduced staining for GFAP (a and d), and vimentin
(vim; b and e), compared with control treated cells after 8 h. At higher magnifications (insets), filamentous staining for GFAP and vimentin was disrupted, resulting in formation of
IF aggregates (arrows). In comparison, filamentous actin remained unaffected (c and f). (n= 3, scale bars indicate 100 μm. Identical exposures were used for all treatments).
(g–l) WFA treatment in vivo similarly disrupts GFAP and vimentin in retinal flatmounts, but not S100A. (n= 3, scale bars indicate 100 μm. Identical exposures were used for all
treatments)
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found, compared with positive controls (Figure 3j–l). We also
stained retinas from debrided eyes for vascular changes with
CD31 and observed no differences from non-debrided
controls, as previously reported27 (Figure 3m and n). There-
fore, we confirmed that this model does induce robust and
consistent astrocyte and Müller glial reactivity in the inner
Neuroprotective targeting of reactive gliosis
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retina with no evidence of accompanying damage or
inflammatory response.
Activation of retinal astrocytes increases neuronal
vulnerability in an IF and p38 MAPK-dependent manner.
Our initial experiment treatment with WFA or SB potently
blocked KA-induced astrocyte activation and neuronal
apoptosis, but each inhibitor could also act through additional
mechanisms to directly affect neurons. In particular, SB has
been proposed to directly inhibit p38-dependent RGC
apoptosis.51 Therefore, we designed a combined experiment
in which KA challenge was combined with, or without,
induced astrocyte activation in order to isolate the influence
of the IF-mediated reactivity response.
In this combined design retinal astrogliosis was induced by
debridement injury one week before KA challenge, along with
each drug treatment or vehicle (Figure 4a). In naive, non-
debrided eyes, KA treatment-induced moderate glial activa-
tion and GCL apoptosis as previously described (Figure 4b
and c). In comparison, corneal debridement-induced massive
reactivity in combination with KA challenge (Figure 4d). This
combination also produced a marked increase in GCL
apoptosis compared with KA alone (Figure 4e). Quantification
of these results demonstrated a highly significant 16-fold
increase in glial reactivity in debrided eyes compared with KA
alone, and a 7-fold increase in apoptosis (Figure 4j and k).
However, these increases were completely rescued by
administration of either WFA or SB (Figure 4f–k). This
experiment therefore provides evidence that induced glial
reactivity increases the vulnerability of retinal neurons to
excitotoxic injury, and that WFA and SB mediate their
protective effects through blocking this switch.
WFA inhibits p38 MAPK-dependent TNF-α secretion.
Neuronal apoptosis in the inner retina following disease and
excitotoxic injury has been previously shown to be dependent
on cytokine signals secreted by adjacent astrocytes.33,34,50,52
Therefore we investigated WFA- and SB-regulated cytokines
that might explain the IF-dependent effects in our models.
Starting with cultured astrocytes, conditioned media was
collected from treated cells and subjected to multiplex
cytokine analyses. In this case the cells were stressed by
serum deprivation to facilitate collection and analyses of
conditioned media. Surprisingly, out of a panel of 27
cytokines and growth factors assessed, only TNF-α levels
were significantly altered by WFA, although, negative trends
were also identified for IL-1α and β, and EGF, and a positive
trend for IL-10 (Table 1). TNF-α concentrations were strongly
reduced by WFA treatment, in a dose-dependent manner to
2 μM (Figure 5a). To test whether this TNF-α signal was also
dependent on downstream p38 MAPK signaling, cells were
alternatively treated with SB, which we have previously
reported to effectively block reactivity markers.29 SB treat-
ment reduced TNF-α levels to below detection (Figure 5b).
Western blotting demonstrated that increasing concentra-
tions of WFA reduced GFAP in cultured retinal astrocytes, but
not the intermediate filament β-tubulin (β-tub) (Figure 5c).
Furthermore, phospho-p38 MAPK signal (p-p38) was
reduced compared with total p38 (Figure 5c), consistent with
previous reports.25,26 In comparison, levels of IκBα were
unaffected up to 2 μM (Figure 5c). Therefore, the WFA-
induced effect on TNF-α may be mediated through p38
MAPK in retinal astrocytes.
Glial derived TNF-α has been closely linked to the induction
of neuronal apoptosis in a variety of acute and degenerative
models, including following excitotoxic injury,33,53–55 and
during progression of glaucoma.34,56,57 To confirm the effects
of WFA on secretion of TNF-α, we probed retinal sections from
KA challenged and control eyes with antibodies to TNF-α to
observe the effect of IF inhibition in vivo.
In KA challenged eyes TNF-α staining was prominently
localized in the inner retina, matching the observed pattern of
apoptosis in the GCL and INL, but was not present in the outer
retinal layers (Figure 5d and e; Supplementary Figure 2).
Correspondingly, TNF receptor 1 (TNFR1) staining primarily
localized to GCL neurons (Supplementary Figure 2), consis-
tent with previous reports.33,34 In comparison, sections from
KA challenged eyes treated with WFA or SB showed strongly
reduced TNF-α signal (Figure 5f–i). This TNF-α signal was
quantified by measuring the average staining intensity across
theGCL frommultiple sections per animal, for multiple animals
in each treatment group. Results indicated a significant
reduction of TNF-α inWFA- and SB-treated animals compared
with control (Figure 5j). Reduced TNF-α signal in retinal
lysates was further confirmed by western blot (Figure 5k).
Thus, treatment with WFA or SB reduced TNF-α signal in the
inner retina following injury in vivo.
Discussion
Astrocyte reactivity is associated with many neurodegenera-
tive and neurotoxic processes, including Alzheimer’s disease,
Parkinson’s disease, stroke, diabetic retinopathy and
glaucoma.3,32,58–60 This parainflammatory switch contributes
to progression of non-cell autonomous disease
mechanisms.4,61 However, the pathogenic cascades under-
lying reactivity have proven difficult to study in vivo due to a
lack of pharmacologic tools to modulate this process. Genetic
deletion of vimentin or GFAP results in compensatory changes
in remaining IF’s. Although double knockouts of GFAP and
vimentin promote axonal outgrowth and regeneration in
developing neurons and after CNS injury,10–12 and use of glial
Figure 3 Rapid retinal glial reactivity is induced by corneal injury in the absence of cell death or inflammation. (a and b) Non-debrided control eyes show no evidence of gliosis
or cell death. (c and d) Mechanical debridement of the corneal epithelium in the contralateral eye results in strongly increased GFAP staining in retinal astrocytes and Müller glia
by 7 days (c), but no evidence of cell death or disrupted morphology (d). (e) Western blots from whole retina lysates show increased GFAP and decreased GS. (f) Densitometry
and statistical analyses from multiple blots confirming the changes in e (bars represent SE, *Po0.05, n= 3 animals). (g–i) Staining of debrided retinas for activated microglia,
neutrophils and macrophages, was largely negative with CD68, GR-1 and F4/80 antibodies, respectively. (j–l) Corresponding antibody-positive controls from eyes treated with
150 mM NaOH. (m and n) There was no change in retinal blood vessel staining with the endothelial marker CD31 between control (m) or debrided eyes (n). (Scale bar indicates
50 μm, Con; control, Deb; debrided.)
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toxins is similarly protective.42 Yet, these deletions also result
in developmental and pathologic defects in CNS patterning
and function that can alter baseline tissue homeostasis.13–15
In order to fully test the role of IF dynamics during glial
reactivity and disease, pharmacological tools are necessary to
block increased activity on a normal background. Here we
Neuroprotective targeting of reactive gliosis
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have presented data demonstrating that pharmacologic
inhibition of glial IF dynamics blocks p38 MAPK-dependent
secretion of TNF-α, and dramatically reduces apoptosis in a
non-cell autonomous model of excitotoxic neuronal death.
WFA is the cardinal member of a family of bioactive steroidal
lactones termed ‘withanolides’, derived from the Withania
somnifera plant.62 It is a potent inhibitor of vimentin polymer-
ization, and has been primarily investigated for anti-angio-
genic, cytostatic, and anti-inflammatory effects, particularly
through modulation of NFκB and MAPK signaling. Recent
studies have clarified the mechanism of WFA to specifically
target type III intermediate filaments, including vimentin and
GFAP.16,27 Additionally, multiple labs have demonstrated that
its downstream kinase and transcriptional effects, as well
cytostatic effect at high concentration, are dependent on IF
blocking activity.16,20,25,27,63,64 Therefore, WFA provides a
potent tool for probing the efficacy of IF disruption in the
context of neuronal injury. Interestingly, Swarup et al.65
reported improved CNS outcomes following WFA administra-
tion in a model of amyotrophic lateral sclerosis, but did not
explore these results in the context of IF inhibition.
In our experiments pharmacologic blockade of IF dynamics
in reactive glia with WFA-protected retinal neurons from
excitotoxic metabolic stress. In the inner retina astrocyte
processes and Müller glia endfeet interact closely with RGC
bodies and axons to regulate inner retinal homeostasis.8,31,58
Reactive gliosis is rapidly induced following insult to the inner
retina,7,66 and is associated with cytokine secretion, remodel-
ing of the optic nerve head, loss of glutamate buffering and
increased production of detoxifying enzymes.8,58,67–69 Our
results suggest that the anti-apoptotic activity of WFA is
mediated by inhibiting a p38 MAPK-dependent production of
TNF-α by reactive astrocytes and Müller glia. Inhibition of IFs
or p38 MAPK-reduced glial reactivity, and inhibited neuronal
cell death. In contrast, a new model of induced glial reactivity
markedly increased susceptibility to excitotoxic death. WFA or
SB might act through additional mechanisms to directly affect
neurons, as previously reported for SB.51 Therefore, we
performed a combined experiment of KA challenge with
induced glial activation to demonstrate a rescue of the
reactivity-mediated injury by treatment with WFA or SB.
To explain these results we show that IF inhibition blocked
p38 MAPK phosphorylation, and p38-dependent secretion of
TNF-α. In comparison, IκBα levels were unchanged, suggest-
ing that NFκB signaling was not strongly affected. Increased
p38 phosphorylation and signaling has been closely asso-
ciated with astrocyte and microglia reactivity in the context of
oxidative and metabolic stress through regulation of antiox-
idant defense, mitochondrial function and cytokine secretion,
particularly TNF-α.29,70,71 In addition, gain of function accu-
mulations of mutant GFAP protein causes Alexander’s
disease via a p38 MAPK-dependent pathology.15 Accordingly,
inhibition of p38 signaling is protective in models of metabolic
and oxidative neuronal injury.51,72,73
A cytokine screen identified that WFA significantly reduced
TNF-α release, although a trend for negative regulation was
also identified for IL-1α and β, and EGF, and a positive trend for
IL-10. IL-10 has been reported to play a role in astrocyte
mediated neuroprotection, through direct and indirect
mechanisms.74–77 Therefore, these additional factors may
also contribute to the observed efficacy. TNF-α is a key
proinflammatory cytokine that binds to two major death
receptors (TNFR1 and TNFR2) to induce the extrinsic
apoptosis cascade.55 Non-cell autonomous neuronal cell
death due to glial derived TNF-α signaling has been implicated
in a diverse range of neurodegenerative and neurotoxic
conditions,55 including excitotoxicity.33,53 In the eye, TNF-α
secretion by reactive astrocytes and Müller glia has been well
established to induce RGC apoptosis in experimental
models,52,54 and during degenerative disease.34,56 Subse-
quently, pharmacologic inhibition or genetic deletion of TNF-α
signaling is protective to RGCs.33,54 The present results
suggest that type III IF dynamics initiate a p38—TNF-α
signaling cascade in reactive glia that exacerbates inner
retinal injury. In addition, the inhibition of p38 MAPK
Figure 4 Induced glial reactivity promotes inner retinal apoptosis and is rescued by IF and p38 MAPK inhibition. (a) Schematic for induction of retinal gliosis by corneal
debridement, followed by drug or vehicle treatments and KA challenge. (b and c) KA challenge induced rapid gliosis and GCL death as previously. (d and e) Prior corneal
debridement-induced increased GFAP accumulation and increased GCL apoptosis following KA insult (arrows). Treatment with WFA (f and g) or SB (h and i) rescued the
debridement-induced gliosis and cell death. (j and k) Quantification of the results showing that gliosis induced GCL death in WFA and SB-treated animals is significantly reduced
(bars are S.E., **Po0.01, n⩾ 6 animals). Scale bar indicates 50 μm
Table 1 Media cytokines after WFA treatment
Analyte Normalized concentrations
Vehicle 2 μM WFA
TNF-αa 1.00 0.38
IL-1α 1.00 0.50
EGF 1.00 0.55
IL-1β 1.00 0.62
LIX 1.00 0.90
IL-6 1.00 0.91
RANTES 1.00 0.95
MIP-2 1.00 0.98
VEGF 1.00 1.01
IP-10 1.00 1.08
Leptin 1.00 1.16
IL-13 1.00 1.18
GRO/KC 1.00 1.20
IL-2 1.00 1.21
IL-12(p70) 1.00 1.22
IL-5 1.00 1.28
MCP-1 1.00 1.29
Fractalkine 1.00 1.45
IL-4 1.00 1.52
IFNy 1.00 1.59
IL-18 1.00 1.70
MIP-1α 1.00 1.74
GM-CSF 1.00 1.86
Eotaxin 1.00 2.24
IL-17A 1.00 2.39
IL-10 1.00 4.36
G-CSF — —
Abbreviation: WFA, withaferin A.
aPo0.05, n= 3 isolates from eight animals each
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conversely decreased IF accumulation. As both p38 and TNF-
α have roles in the induction of astrocyte reactivity,29,71,78 it
seems likely that an autocrine loop is at play that may include
additional mediators, such as IL-10. Future experimentswill be
required to fully elucidate this signaling cascade.
Excitotoxic damage due to elevated glutamate has been
associated with many acute and chronic neurodegenerative
diseases of the retina and brain, including stroke, Alzheimer’s
disease and glaucoma.31,32,79 The inner retina is particularly
vulnerable to excitotoxic and metabolic stress, which is
exacerbated through the release of TNF-α by neighboring
astrocytes and Müller glia.28,33 However, the astrocyte
reactivity cascade is a complex process that has both positive
and negative aspects. For example, ischemic preconditioning
Figure 5 WFA treatment inhibits p38 MAPK-dependent TNF-α secretion in the inner retina. (a) Conditioned media from astrocytes treated with WFA showed a dose-
dependent decrease in TNF-α concentrations (*Po0.05, n= 3 cultures). (b) Conditioned media from astrocytes treated with 15 μm SB showed a complete loss of detectable
TNF-α (n= 3 cultures). (c) Western blot showing increasing concentrations of WFA resulted in reduced GFAP protein and phospho-p38 MAPK (p-p38), compared with pan-p38
MAPK. In comparison there was no change in β-tub, IκBα, or a GAPDH loading control. (d and e) Staining for TNF-α (red) appears strongly in the inner retina in KA challenged
eyes (arrow). (f and g) Treatment with WFA, or (h and i) SB, reduced TNF-α staining. Cell nuclei are indicated by Dapi staining in all images (blue). (j) Quantification of TNF-α
intensity across the GCL confirms a reduced signal in WFA- or SB-treated eyes following KA challenge (*Po0.05, n= 3 animals per group). Scale bar represents 50 μm.
(k) Western blot of retinal lysates similarly shows increased TNF-α signal following KA challenge that is blocked by WFA treatment, compared with GAPDH loading control
(n= 4 animals per lane)
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has been reported to have protective effects that are partially
attributed to activated glia.80–82 The mechanism underlying
this protection remains unclear, and is likely influenced by
signaling through additional metabolic response pathways
that may differ from the p38 driven mechanism we have
described here. A key goal for the present work is the targeted
inhibition of IFs, rather than complete ablation of the reactive
cascade. Here we have demonstrated that pharmacologic
targeting of IF dynamics modulates cytokine release and
dramatically reduces neuronal cell death following acute
retinal injury. It will be important for future studies to expand
these findings by using WFA as a probe to further investigate
the roles and mechanisms of glial IF dynamics in other
neurotoxic and neurodegenerative processes.
Materials and Methods
Retinal injury model. All animal experiments were approved by the UHN
Animal Care Committee in accordance with applicable regulations. Male C57BL/6
mice were anesthetized by i.p. injection of ketamine/xylazine. Intravitreal injections
with 10 mM kainic acid (KA) were performed as previously described.28 Briefly, a
30 g needle was inserted tangentially into the vitreous and replaced with a Hamilton
syringe to inject a volume of 2 μl, followed by application of ophthalmic antibiotic
ointment (BNP, Vetoquinol). For drug experiments, mice received two injections of
either vehicle, 2 mg/kg WFA i.p., or 2 mM SB203580 (Selleckchem, Burlington, ON,
Canada) intravitreally, the day before, and 1 h before KA challenge. Eighteen hours
after KA challenge mice were euthanized by CO2 asphyxiation and eyes processed
for histopathology. In all experiments n refers to the number of animals tested.
Induced glial reactivity model. Corneal epithelial debridement was
performed to induce retinal glial reactivity as previously described.27,48 Briefly,
anesthetized mice received topical proparacaine to the eyes (Bausch and Lomb,
Vaughan, ON, Canada). Eyes were proptosed with forceps, and the corneal
epithelium was gently removed with a sterile disposable scalpel, followed by
application of antibiotic ointment. For some experiments, at 6 and 7 days post
debridement, mice received injection of either vehicle, 2 mg/kg WFA i.p., or 2 mM
SB203580 intravitreally, followed by KA challenge, as described above. The retinas
were processed on day eight as described above. In all experiments n refers to the
number of animals tested.
Astrocyte cultures. Primary mature retinal astrocytes were isolated and
cultured as previously described.30 Briefly, retinas were dissected out of adult Wistar
rat eyes and placed in ice-cold MEM-H17 culture medium. Retinas were digested by
shaking in MEM-H17 containing trypsin and DNAse, followed by trituration to
disperse cell aggregates. When cultures reached confluence, the cells were placed
on a rotating shaker for 6–8 h and re-plated. A glial-specific expression profile was
confirmed by probing the resulting cells with a marker panel. For staining and
biochemistry experiments media was replaced with serum-free media and cultured
for an additional 8 h with treatment of 0.5 or 2.0 μM WFA, 15 μM SB or the
equivalent DMSO vehicle as a control. Conditioned media was collected after 8 h
and immediately frozen for multiplex cytokine analyses.
Western blotting and cytokine profiling. Cells were lysed in RIPA buffer
containing Complete Mini EDTA-free protease inhibitor (Roche) and PhosSTOP
phosphatase inhibitor (Roche, Mississauga, ON, Canada). Total protein was
quantified and equal concentrations were submitted to SDS-PAGE by standard
methods. Proteins were transferred to PVDF membrane and probed with antibodies
raised against GFAP (Sigma, St. Louis, MO, USA), GS (Abcam, Cambridge, MA,
USA), phospho-p38 and pan-p38 MAPK (Cell Signaling, Danvers, MA, USA), IκBα
(Santa Cruz, Dallas, TX, USA), TNF-α (R&D Systems, Minneapolis, MN, USA), and
GAPDH (Calbiochem, San Diego, CA, USA), and detected with appropriate IRDye
secondary antibody (Li-Cor Biosciences, Lincoln, NE, USA). Blots were imaged with
an Odyssey infrared imaging system (Li-Cor Biosciences). For TNF-α and multiplex
cytokine profiling, conditioned media was snap frozen and submitted for laser bead
analyses on a Bioplex 200 to detect sensitive and quantitative target protein
concentrations against a standard curve (Eve Technologies).
Immunofluorescence microscopy. Enucleated eyes were fixed in 4%
PFA overnight. Eyes were then equilibrated in 30% sucrose for 12 h, embedded in
OCT, and cryosectioned at 16 μM. Sections were blocked and probed with primary
antibodies to GFAP (Sigma), GS (Sigma), CD68 (Biolegend, San Diego, CA, USA),
GR-1 (Biolegend), F4/80 (Biolegend), TNF-α (R&D Systems), RBPMS (Phospho-
solutions, Aurora, CO, USA), and CD31 (BD Biosciences, Mississuaga, ON,
Canada) according to standard protocols. Following PBS-t washes, sections were
incubated with fluorescent-conjugated 2° abs (Molecular Probes, Eugene, OR,
USA) and mounted with DAPI. TUNEL staining was performed according to the
manufacturer’s instructions (DeadEnd; Promega, Fitchburg, WI, USA). Briefly,
sections were fixed with 4% PFA for 5 min and washed in PBS. Equilibration buffer
was added, and rTdT reaction mix was applied to each slide and incubated at 37 °C
for 60 min. Slides were immersed in 2 × SSC and then washed with PBS, followed
by blocking with 5% goat serum and incubation with 1° abs at 4 °C. Images were
acquired with a Zeiss AxioImager fluorescence microscope. For in vitro staining,
cells were washed, fixed in 4% PFA for 15 min, rinsed and permeabilized in 0.2%
Triton X-100 for 15 min, and blocked with 5% BSA for 1 h. Cells were probed
with 1° abs to: GFAP (Abcam), Vimentin (Sigma), or rhodamine phalloidin (Life
Technologies, Burlington, ON, Canada), O/N at 4 °C, followed by washing and the
appropriate Alexa Fluor 2° abs antibodies (Life Technologies) for 1 h. Cells were
mounted with Vecta-Shield anti-fade medium with DAPI (Vector Labs, Burlingame,
CA, USA), and imaged on an inverted Nikon TIE-E fluorescent microscope.
Image analyses. To quantifying glial reactivity, retinal sections were imaged at
the level of the optic nerve. The proportion of increased GFAP immunostaining in
Müller cell processes was used as an established approach to quantify retinal glial
reactivity.43 Briefly, for each animal GFAP-immunopositive processes were counted
in the inner plexiform layer for at least five retinal sections at the level of the optic
nerve. GFAP-positive processes were counted for each eye and expressed as the
average number of positive processes per 100 μm.60 To quantify the extent of
apoptosis, we counted the number of TUNEL-positive nuclei in the GCL and
expressed it as a fraction of the total GCL nuclei. In treated eyes the TUNEL signal
was more difficult to find, so we conservatively counted any suspected labeling in
our analyses. For each eye, at least five central retinal sections were analyzed at
the level of the optic nerve stretching to each ora serrata, and the results averaged,
as previously described.28,44–46,83 For TNF-α staining the mean intensity of antibody
signal was measured in the GCL and normalized to the slide background for each
section. Intensity readings were averaged for at least three sections at the level of
the optic nerve for each eye, and then averaged across each treatment group as
indicated. For all experiments eyes from at least three animals were assessed with
specific numbers described in each figure legend. Statistical analyses were
performed by one-way ANOVA with TUKEY post hoc analyses.
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